Zeichner et al. found a mortality rate lower than 31% among HER2+ nonmetastatic breast cancer patients who took more than 10,000 IU/week (International Units/week), instead of less than 10,000 IU/week [17], showing a potential booster effect of the trastuzumab-based chemotherapy. This evidence concerns the gene ERBB2 and breast carcinoma.